Request Demo
Recent blog posts
Latest Hotspot
8 min read
HYR-PB21 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
HYR-PB21: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Antineoplaston A10 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Antineoplaston A10: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Bronchiectasis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Bronchiectasis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Skin Prick Solution for Blattella Germanica (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Blattella Germanica (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals.
Latest Hotspot
8 min read
Progressive Pulmonary Fibrosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Progressive Pulmonary Fibrosis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…
Latest Hotspot
8 min read
Skin Prick Solution for Cat Fur (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Cat Fur (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Idiopathic Pulmonary Fibrosis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Idiopathic Pulmonary Fibrosis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Skin Prick Solution for Platanus Acerifolia Pollen (Wolwo Bio-Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Skin Prick Solution for Platanus Acerifolia Pollen (Wolwo Bio-Pharmaceutical): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP.
Latest Hotspot
8 min read
COPD Disease Modification Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 COPD Disease Modification clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Citrulline Malate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Citrulline Malate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Severe Eosinophilic Asthma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Severe Eosinophilic Asthma clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Tetravalent vaccine (ApicHope Pharmaceutical) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Tetravalent dengue virus vaccine(Instituto Butantan): Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.